Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E

References

• Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet344, 793–795 (1994).
   PubMed Web of Science ®Google Scholar
• Singh U, Devaraj S, Jialal I. Vitamin E, oxidative stress and inflammation. Ann. Rev. Nutr.25, 151–174 (2005).
   PubMed Web of Science ®Google Scholar
• Johansen JS, Harris A, Rychly D, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Card. Diab.4, 5–15 (2005).
   PubMed Web of Science ®Google Scholar
• Lee DH, Folsom AR, Harnack L, Halliwell B, Jacobs DR. Common presence of non-transferrin bound iron among patients with Type II diabetes. Diab. Care29, 1090–1095 (2006).
   PubMedGoogle Scholar
• Ceriello PA. Oxidative stress and diabetes associated complications. Endo. Prac.12, 60–62 (2006).
   Google Scholar
• Wang X, Quinn PJ. Vitamin E and its function in membranes. Prog. Lipid Res.38, 309–316 (1999).
   PubMed Web of Science ®Google Scholar
• Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomized trials. Lancet361, 2017–2023 (2003).
   PubMed Web of Science ®Google Scholar
• Renard C, Van Obberghen E. Role of diabetes in atherosclerosis pathogenesis. What have we learned from animal models? Diab. Metab.32, 15–29 (2006).
   PubMedGoogle Scholar
• Otero P, Bonet B, Herrera E, Rabano A. Development of atherosclerosis in the diabetic BALB/c mice. Prevention with vitamin E administration. Atherosclerosis182, 259–265 (2005).
   PubMed Web of Science ®Google Scholar
• Gaziano JM. Vitamin E and cardiovascular disease: observational studies. Ann. NY Acad. Sci.1031, 280–291 (2004).
   PubMed Web of Science ®Google Scholar
• Forman D, Altman D. Vitamins to prevent cancer: supplementary problems. Lancet364, 1193–1194 (2004).
   PubMedGoogle Scholar
• Miller ER, Barriuso RP, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high dosage vitamin E supplementation may increase all cause mortality. Ann. Intern. Med.142, 37–46 (2005).
   PubMed Web of Science ®Google Scholar
• HOPE and HOPE-2 Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer. JAMA293, 1338–1347 (2005).
   PubMed Web of Science ®Google Scholar
• Brown BG, Crowley J. Is there any hope for vitamin E? JAMA293, 1387–1390 (2005).
   PubMed Web of Science ®Google Scholar
• Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation105, 2107–2111 (2002).
   PubMed Web of Science ®Google Scholar
• Lee IM, Cook NR, Gaziano JM et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Womens Health Study: a randomized controlled trial. JAMA294, 56–65 (2005).
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins or the combination for the prevention of coronary disease. N. Engl. J. Med.345, 1583–1592 (2001).
   PubMed Web of Science ®Google Scholar
• HOPE Trial Investigators. Vitamin E supplementation and cardiovascular events in high risk patients. N. Engl. J. Med.342, 154–161 (2000).
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high risk individuals; a randomized placebo controlled trial. Lancet360, 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomized placebo controlled trial. Lancet356, 1213–1218 (2000).
   PubMed Web of Science ®Google Scholar
• Simon R, Wang SJ. Use of genomic signatures in therapeutics development in oncology and other diseases. Pharmacogenomics6, 166–173 (2006).
   Google Scholar
• Bowman BH, Kurosky A. Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv. Hum. Genet.12, 189–261 (1982).
   PubMed Web of Science ®Google Scholar
• Levy AP, Hochberg I, Jablonski K et al. Haptoglobin phenotype and the risk of cardiovascular disease in individuals with diabetes: the Strong Heart Study. J. Am. Coll. Card.40, 1984–1990 (2002).
   PubMed Web of Science ®Google Scholar
• Roguin A, Koch W, Kastrati A, Aronson D, Schomig A, Levy AP. Haptoglobin genotype is predictive of major adverse cardiac events in the one year period after PTCA in individuals with diabetes. Diab. Care26, 2628–2631 (2003).
   PubMed Web of Science ®Google Scholar
• Suleiman M, Aronson D, Asleh R et al. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes19, 2802–2806 (2005).
   Google Scholar
• Levy AP, Levy JE, Kalet-Litman S et al. Haptoglobin genotype is a determinant of iron, lipid peroxidation and macrophage accumulation in the atherosclerotic plaque. Arterioscl. Thromb. Vasc. Biol.27, 1419–1425 (2007).
   Google Scholar
• Miller-Lotan R, Miller B, Aronson D, Asaf R, Nakhoul F, Levy AP. Retinal capillary basement membrane thickness in diabetic mice genetically modified at the haptoglobin locus. Diab. Met. Res. Rev.23, 152–156 (2007).
   PubMedGoogle Scholar
• Miller-Lotan R, Herskowitz Y, Kalet-Litman S et al. Increased renal hypertrophy in diabetic mice genetically modified at the haptoglobin locus. Diab. Met. Res. Rev.21, 332–337 (2005).
   PubMedGoogle Scholar
• Blum S, Asaf R, Guetta J et al. Haptoglobin genotype determines myocardial infarct size in diabetic mice. J. Am. Coll. Card.49, 82–87 (2007).
   PubMed Web of Science ®Google Scholar
• Asleh R, Miller-Lotan R, Aviram M et al. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circ. Res.99, 1419–1425 (2006).
   PubMed Web of Science ®Google Scholar
• Sadrzadeh SMH, Graf E, Panter SS et al. Hemoglobin - a biologic Fenton reagent. J. Biol. Chem.259, 14354–14356 (1984).
   PubMed Web of Science ®Google Scholar
• Frank M, Lache O, Enav B et al. Structure/function analysis of the anti-oxidant properties of haptoglobin. Blood98, 3693–3698 (2001).
   PubMed Web of Science ®Google Scholar
• Miller YI, Altamentova SM, Shaklai N. Oxidation of low density lipoprotein by hemoglobin stems from a heme initiated globin radical: antioxidant role of haptoglobin. Biochemistry36, 12189–12198 (1997).
   PubMed Web of Science ®Google Scholar
• Hershko C. The fate of circulating hemoglobin. Br. J. Hematol.29, 199 (1975).
   PubMed Web of Science ®Google Scholar
• Kristiansen M, Graversen JH, Jacobsen C et al. Identification of the hemoglobin scavenger receptor. Nature409, 198–201 (2001).
   PubMed Web of Science ®Google Scholar
• Graversen JH, Madsen M, Moestrup SK. CD163: a signal receptor scavenging haptoglobin hemoglobin complexes from plasma. Int. J. Biochem. Cell Biol.234, 309–314 (2002).
   Google Scholar
• Levy AP, Moreno PR. Intraplaque hemorrhage. Curr. Mol. Med.6, 479–488 (2006).
   PubMed Web of Science ®Google Scholar
• Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype and diabetes dependent differences in iron mediated oxidative stress in vitro and in vivo. Circ. Res.96, 435–441 (2005).
   PubMed Web of Science ®Google Scholar
• Rich RL, Myszka DG. Advances in surface plasmon resonance biosensor analysis. Curr. Opin. Biotech.11, 54–61 (2000).
   PubMed Web of Science ®Google Scholar
• Bamm VV, Tsemakhovich VA, Shaklai M, Shaklai N. Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL. Biochemistry43, 3899–3906 (2004).
   PubMed Web of Science ®Google Scholar
• Asleh R, Marsh S, Shiltruck M et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ. Res.92, 1193–1200 (2003).
   PubMed Web of Science ®Google Scholar
• Moreno PR, Purushothaman KR, Sirol M, Levy AP, Fuster V. Neovascularization in human atherosclerosis. Circulation113, 2245–2252 (2006).
   PubMed Web of Science ®Google Scholar
• Esposito K, Nappo F, Marfella R et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans. Role of oxidative stress. Circulation106, 2067–2072 (2002).
   PubMed Web of Science ®Google Scholar
• Shanmugam N, Reddy MA, Guha M, Natarajan R. High glucose induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes52, 1256–1264 (2003).
   PubMed Web of Science ®Google Scholar
• Levy AP, Gerstein HC, Miller-Lotan R et al. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diab. Care27, 2767 (2004).
   PubMed Web of Science ®Google Scholar